SCHEMBL2762767

SCHEMBL2762767

CC(=O)Nc1ccc(-c2csc(NS(=O)(=O)c3cccc(Cl)c3C)n2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.62
KDM1A O60341 3/20 0.59
MAOA P21397 3/20 0.59
KMT2A Q03164 9/20 0.55
MEN1 O00255 8/20 0.55
RAB9A P51151 4/20 0.55
NPC1 O15118 3/20 0.55
NFKB1 P19838 1/20 0.55
STAT1 P42224 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
HSD11B1 P28845 3/20 0.54
HSD17B1 P14061 2/20 0.54
HSD17B2 P37059 2/20 0.54
GAA P10253 3/20 0.54
GFER P55789 1/20 0.54
ALDH1A1 P00352 4/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
LMNA P02545 2/20 0.53
MAPK1 P28482 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2763208 0.89 MAPT (0.64) MAPTKDM1AMAOAKMT2AMEN1
SCHEMBL2762614 0.85 KDM1A (0.69) KDM1AMAOAKMT2AMEN1HSD11B1
SCHEMBL2762593 0.85 MAPT (0.65) MAPTKDM1AMAOAKMT2AMEN1
SCHEMBL2762719 0.82 KDM1A (0.66) MAPTKDM1AMAOAKMT2AMEN1
SCHEMBL5966335 0.82 MAPT (0.64) MAPTKDM1AMAOAKMT2AMEN1
SCHEMBL2762771 0.81 MAPT (0.63) MAPTKDM1AMAOAKMT2AMEN1
SCHEMBL2762675 0.80 MAPT (0.59) MAPTKDM1AMAOAKMT2AMEN1
SCHEMBL2762234 0.79 KDM1A (0.57) MAPTKDM1AMAOAKMT2AMEN1
SCHEMBL2763006 0.79 KDM1A (0.61) KDM1AMAOAKMT2AMEN1RAB9A
SCHEMBL2762518 0.79 KDM1A (0.65) KDM1AMAOAKMT2AMEN1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1283832-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-10-20 EP claimed
US-7132436-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-11-07 US claimed
WO-2004112783-A1 NEW USE IV BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 CLARIO TECH LIMITED (GB) 2003-09-04 US claimed
EP-1283832-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-10-20 EP disclosed
US-7132436-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-11-07 US disclosed
WO-2004112783-A1 NEW USE IV BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 CLARIO TECH LIMITED (GB) 2003-09-04 US disclosed
EP-1283832-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 EP disclosed
WO-2001090092-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 MAPT 3275/4885KDM1A 1332/4885MAOA 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.